Edwards Lifesciences (NYSE:EW) had its price objective decreased by analysts at Evercore ISI from $130.00 to $122.00 in a research report issued to clients and investors on Thursday, PriceTargets.com reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s price target indicates a potential upside of 16.33% from the stock’s previous close.
A number of other equities research analysts also recently commented on EW. Piper Sandler cut their target price on shares of Edwards Lifesciences from $133.00 to $125.00 in a research report on Thursday. Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $126.00 target price for the company in a research report on Monday, December 6th. Citigroup cut their target price on shares of Edwards Lifesciences from $142.00 to $138.00 and set a “buy” rating for the company in a research report on Thursday. Morgan Stanley cut their target price on shares of Edwards Lifesciences from $148.00 to $136.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, UBS Group cut their price objective on shares of Edwards Lifesciences from $125.00 to $121.00 and set a “neutral” rating for the company in a research report on Thursday. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $123.76.
NYSE EW opened at $104.87 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.64 and a quick ratio of 2.87. The stock has a market capitalization of $65.47 billion, a PE ratio of 44.63, a PEG ratio of 3.26 and a beta of 1.10. Edwards Lifesciences has a 1 year low of $78.44 and a 1 year high of $131.73. The business’s 50-day moving average is $118.42 and its 200 day moving average is $116.17.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, January 25th. The medical research company reported $0.51 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.55 by ($0.04). Edwards Lifesciences had a return on equity of 28.13% and a net margin of 29.00%. During the same quarter in the previous year, the business earned $0.50 earnings per share. As a group, equities research analysts anticipate that Edwards Lifesciences will post 2.26 earnings per share for the current year.
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,050 shares of the business’s stock in a transaction on Friday, November 5th. The shares were sold at an average price of $117.17, for a total value of $1,294,728.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,550 shares of the business’s stock in a transaction on Thursday, January 6th. The stock was sold at an average price of $123.88, for a total transaction of $4,032,294.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 167,160 shares of company stock worth $20,126,910. 1.35% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in EW. Liberty Wealth Management LLC lifted its stake in Edwards Lifesciences by 362.3% in the 3rd quarter. Liberty Wealth Management LLC now owns 245 shares of the medical research company’s stock worth $29,000 after purchasing an additional 192 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $30,000. West Oak Capital LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $34,000. Arlington Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $34,000. Finally, Canton Hathaway LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 80.79% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.
Further Reading: Asset Allocation, Balancing Your Investments
Want More Great Investing Ideas?